Off-patent drugs in Italy: A short-sighted view?

European Journal of Health Economics

Volumn 7, Issue 1, 2006, Pages 79-83

  Garattini, Livio ^a   Ghislandi, Simone ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Generics; Italy; Pharmaceutical policy

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; GENERIC DRUG; LANSOPRAZOLE; NIMESULIDE; OMEPRAZOLE; RANITIDINE; TICLOPIDINE;

COMPETITION; DRUG COST; DRUG MARKETING; DRUG SUBSTITUTION; HEALTH CARE POLICY; ITALY; PATENT; PRIORITY JOURNAL; REVIEW;

DRUGS, GENERIC; HUMANS; ITALY; LEGISLATION, DRUG; PATENTS; PHARMACEUTICAL PREPARATIONS;

EID: 33644852185     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-005-0335-9     Document Type: Review

References (11)

1. Ghislandi S, Krulichova I, Garattini L (2004) Pharmaceutical policy in Italy: towards a structural change? Health Policy 72:53-63
2. Danzon P (2001 ) Reference pricing: theory and evidence. In Lopez-Casanovas G, Jonsson B (eds) Reference pricing and pharmaceutical policy. Springer Iberica: Barcelona, pp 86-126
3. Garattini L, Tediosi F (2000) A comparative analysis of generics markets in five European countries. Health Policy 51:149-162
4. Coscelli A (2000) The importance of doctors' and patients' preferences in the prescription decision. J Ind Econ 48:349-369
5. Danzon P, Chao L (2000) Does regulation drive out competition in pharmaceutical markets? J Law Econ 43:311-357
6. Lopez-Casanovas G, Puig-Junoy J (2000) Review of the literature on reference pricing. Health Policy 54:87-123
7. OsMed (2003) Rapporte nazionale OsMed 2003. Italian Ministry of Health. :http://www.ministerosalute.it/medicinali/osmed, accessed 27 September 2004
8. Puig-Junoy J (2004) Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy 67:149-165
9. Armstrong M, Cowan S, Vickers J (1994) Regulatory reforms: Economic analysis and the UK experience. MIT Press: Boston
10. Martina S, Cornago D, Garattini L (2002) Gruppo di studio I.H.A.G.O. Incentivi ai farmaci generic: a livello di ASL: I'osservatorio I.H.A.G.O." Farma Percorsi Ter 3:71-80
11. Roberts K (2001) Would we be able to recognize a socially desirable reference pricing system if it bit us on the ankle? In Lopez-Casanovas G, Jonsson B (eds) Reference pricing and pharmaceutical policy. Springer Iberica: Barcelona, pp 161-187